PureTech challenges Roche’s Esbriet in head-to-head IPF trialRoche’s idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, Share XPureTech challenges Roche’s Esbriet in head-to-head IPF trialhttps://pharmaphorum.com/news/puretech-challenges-roches-esbriet-in-head-to-head-ipf-trial/
Health Innovators: PureTech Health’s Daphne ZoharIn latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the Share XHealth Innovators: PureTech Health’s Daphne Zoharhttps://pharmaphorum.com/r-d/health-innovators-daphne-zohar-puretech/
Akili’s gaming therapy improves attention in ADHD kidsAkili has published data backing the efficacy of its childhood attention-deficit hyperactivity disorder (ADHD) video game therapy EndeavorRx Share XAkili’s gaming therapy improves attention in ADHD kidshttps://pharmaphorum.com/news/akilis-gaming-therapy-improves-attention-in-adhd-kids/
COVID-19 gives Akili’s digital ADHD treatment an early debut in USAn app to treat children with attention-deficit hyperactivity disorder (ADHD) developed by Akili has been made available ahead Share XCOVID-19 gives Akili’s digital ADHD treatment an early debut in UShttps://pharmaphorum.com/news/covid-19-gives-akilis-digital-adhd-treatment-an-early-debut-in-us/
Karuna raises $68m to develop neurology drug KarXTKaruna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 Share XKaruna raises $68m to develop neurology drug KarXThttps://pharmaphorum.com/news/karuna-raises-68m-to-develop-neurology-drug-karxt/
PureTech to research Alzheimer’s drugs based on ‘brain drain’ theoryUS biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases Share XPureTech to research Alzheimer’s drugs based on ‘brain drain’ theoryhttps://pharmaphorum.com/news/puretech-research-alzheimers-brain-drain-theory/
